Cytokine News and Research

RSS

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

A new study conducted by a team of researchers at Johns Hopkins University, USA, has observed how pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show stunted antiviral immune responses.

18 Nov 2020

Severe COVID-19 complications linked to gut barrier breakdown

A new study claims that severe COVID-19 is caused by a positive feedback loop triggered by systemic inflammation and mediated by abnormal gut permeability. This finding could potentially help open up new avenues of treatment.

18 Nov 2020

SARS-CoV-2 causes a unique cytokine storm, study finds

A new study published on the preprint server medRxiv* in November 2020 reports some of the unique elements of COVID-19-induced CRS and how understanding these distinctive characteristics of the disease could help in formulating specific interventions and therapies.

18 Nov 2020

Hydrogen therapy may help severely ill COVID-19 patients

Researchers from the Department of Critical Care Medicine, Sichuan Provincial People's Hospital, Chengdu in China, have explored the possibility of using hydrogen therapy on severely ill COVID-19 patients. The team published their study's findings, titled "Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients," in the latest issue of the journal Frontiers in Pharmacology.

17 Nov 2020

Nanobodies: unharnessed potential in COVID-19 treatment

A new study published in the Journal of Biomolecular Structure and Dynamics in October 2020 discusses the use of nanobodies in diagnosing and treating this deadly disease.

16 Nov 2020

Metabolic biomarkers could predict COVID-19 severity

A new study suggests that metabolic biomarkers could possibly predict the severity of COVID-19 in patients.

16 Nov 2020

Study sheds new light on the immune system response to COVID-19

A team of immunology experts from research organizations in Belgium and the UK has come together to apply their pioneering research methods to put individuals' COVID-19 responses under the microscope.

16 Nov 2020

Antiviral immune response is suppressed in COVID-19 patients compared to flu patients

Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis led research that suggests most COVID-19 patients are not candidates for treatment with steroids such as dexamethasone.

16 Nov 2020

Baricitinib drug can reduce mortality in patients with moderate to severe COVID-19

The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden.

16 Nov 2020

Study explains why anti-inflammatory drugs benefit only few people with severe COVID-19

The turning point for people with COVID-19 typically comes in the second week of symptoms. As most people begin to recover, a few others find it increasingly difficult to breathe and wind up in the hospital.

16 Nov 2020

Study reveals key role of IL-33 signaling molecule in parasite infections, other health conditions

De'Broski Herbert has a philosophy that's guided his career researching helminths, or parasitic worms, and their interaction with their hosts' immune systems: "Follow the worm."

15 Nov 2020

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

15 Nov 2020

Arthritis drug may improve COVID-19 survival among elderly patients

A type of arthritis drug may reduce the risk of dying for elderly patients with COVID-19.

15 Nov 2020

Antidepressant may prevent worsening of COVID-19 infection, study suggests

The antidepressant fluvoxamine appears to prevent COVID-19 infections from worsening and may help keep patients out of the hospital, a trial based on research from the University of Virginia School of Medicine suggests.

15 Nov 2020

Dopamine-release mechanisms in the brain may play a major role in SARS-CoV-2 infection

The study, which appeared in the Journal of Taibah University Medical Sciences, shows that the SARS-CoV-2 may behave akin to the CNS pathogenic mechanism of JEV and HIV during the early stages of infection.

15 Nov 2020

Human coronaviruses cause processing body loss

Researchers continue to expand their knowledge of coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. Now, a new study published on the preprint server bioRxiv in November 2020 describes a vital mechanism whereby the novel SARS-CoV-2 pathogen can restrict the human host response. In doing so, the study explores how this novel feature of SARS-CoV-2 works and how it results in a reshaping of the human host's immune response.

11 Nov 2020

Research shows a unique T cell receptor repertoire in MIS-C patients

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv in November 2020, as a response to superantigen activation.

11 Nov 2020

Microbes in the lungs could influence lung cancer progression and prognosis

Bottom Line: Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer.

11 Nov 2020

Scientists are developing new treatment option for lung fibrosis

A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.

11 Nov 2020

How SARS-CoV-2 blocks immune response

An international research team has confirmed the mechanism by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Their article titled, “SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling,” is published in the journal Proceedings of the National Academy of Sciences.

11 Nov 2020